FirstWord PharmaOral Semaglutide Significantly Improves Cardiovascular Outcomes in Individuals with Type 2 Diabetes13 hours agoMore
Pharmacy TimesADA 2025: Oral Semaglutide Demonstrates Cardiovascular Benefits in SOUL Trial9 hours agoBy Kennedy FerruggiaMore
Vascular NewsSTRIDE trial analysis confirms potential impact of semaglutide on quality-of-life metrics for PAD patients with diabetes3 hours agoMore
OnlyMyHealthCan Ozempic Lower the Risk of Heart Diseases Within the First 6 Months? Expert Weighs In8 days agoMore
WV NewsSemaglutide Increases Walking Capacity in Patients with Peripheral Artery Disease and Type 2 Diabetes2 days agoMore
HCPLiveSTRIDE: Semaglutide Reduces Progression of PAD by 54% in Type 2 Diabetes2 days agoBy Patrick CampbellMore
Pharmacy TimesADA 2025: Semaglutide Shows Promise in Improving Mobility for Patients With Diabetes and Peripheral Arterial DiseaseYesterdayBy Kennedy FerruggiaMore
Full coverageFull coverage